Lumos Pharma — Q2 2020 Earnings Presentation
14 slides from Lumos Pharma's earnings presentation, Aug 13, 2020
Slide 1: Second Quarter 2020 Financial Results and Corporate Update
Second Quarter 2020 Financial Results and Corporate Update August 13, 2020
Slide 2: Lumos Pharma Q2 2020 Conference Call Agenda
Lumos Pharma Q2 2020 Conference Call • Lisa Miller, Director of Investor Relations • Rick Hawkins, CEO Agenda • John McKew, PhD, COO & CSO • Eugene Kennedy, MD, CMO • Carl Langren, CFO 2
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, within the meaning of The
Slide 4: Sale of Priority Review Voucher (PRV)
Corporate Update – Sale of Priority Review Voucher (PRV) • July 27, 2020 – Merck and Lumos Pharma sign agreement for the sale of the PRV issued in conjunction with approval of Ebola vaccine • Agreed upon value of PRV set at $100 million • Lumos Pharma to be paid $60 million for its 60% interest in P
Slide 5: Clinical and Business Development Activities
Clinical and Business Development Activities • Clinical-stage company focused on therapeutics for rare diseases • Lead asset, LUM-201, with potential to disrupt established pediatric growth hormone deficiency (PGHD) market of over $1 Billion* - LUM-201 oral therapeutic with potential to supplant sig
Slide 6: PGHD and Standard of Care
PGHD and Standard of Care • PGHD occurs due to inadequate secretion of growth hormone by the pituitary gland during childhood • PGHD can be either hereditary or acquired, although the majority of cases have unknown causes (idiopathic) versus - Lack of physical growth is the most obvious manifestatio
Slide 7: LUM-201 Mechanism of Action
LUM-201 Mechanism of Action GHSR1a Hypothalamus • Oral LUM-201 is a growth LUM- hormone (GH) secretagogue SST GHRH 201 • Acts as an agonist of GH GHSR1a Secretagogue Receptor Pituitary (GHSR1a) to stimulate GH release1 • LUM-201 has been observed to GH increase the amplitude of endogenous pulsatile
Slide 8: Targeted PGHD Population
Targeted PGHD Population PEM-Positive: Included PEM-Negative: Excluded GHSR1a GHSR1a Hypothalamus HypothalamusIGF-1 SST GHRH LUM- SST GHRH LUM- 201 201 GHSR1a GHSR1a Pituitary Pituitary GH GH IGF-1 • Functional but reduced HP-GH axis • Non-functional HP-GH axis - Able to secrete some, but insufficie
Slide 9: Phase 2b Trial of LUM-201 in PGHD
Phase 2b Trial of LUM-201 in PGHD • Two main goals set for Phase 2b - Prospectively confirm the utility of PEM strategy - Determine the optimal dose for Phase 3 registration trial • Phase 2b PGHD clinical trial design - Three dose levels of LUM-201 (0.8, 1.6, 3.2 mg/kg) - Positive control arm of dai
Slide 10: Proposed PK/PD Response Supports Doses in PGHD
10 Plasma LUM-201 • PGHD inSupportsDoses Proposed PK/PD Response Concentration (ng/ml) PGHD PGHD dose equivalent* Dose response to 5.6 mg/kg 1000 100 0.1 10 1 0 Pharmacokinetics Merck Study 001 in healthyadult subjects *Dose equivalence isbased on AUC 6 Ti m 12 e ( h r ) 18 24 Plasma GH Concentratio
Slide 11: Pharmacokinetic / Pharmacodynamic Trial of LUM-201 in PGHD
Pharmacokinetic / Pharmacodynamic Trial of LUM-201 in PGHD • Purpose of Pharmacokinetic/Pharmacodynamic (PK/PD) trial - Further explore LUM-201’s mechanism of amplification of natural pulsatile secretion of growth hormone - To expand data package in support of future regulatory filings • PK/PD clini
Slide 12: LUM-201: Other Potential Rare Endocrine Disorders
LUM-201: Other Potential Rare Endocrine Disorders • Beyond PGHD, Prader-Willi Syndrome Small for Gestational Age rhGH FDA approved in 2000 rhGH FDA approved in 2001 Lumos Pharma also plans to investigate LUM-201 for other rare endocrine disorders, for which rhGH has been approved Idiopathic Short St
Slide 13: Secure Cash Position
Secure Cash Position Metric Position Cash balance on June 30, 2020 $72.7 million $60 million for 60% interest in PRV valued at Additional non-dilutive resources anticipated $100 million July 20201 Projected cash use per quarter through 2020 ~ $6.5 to $7.5 million Shares outstanding as of June 30, 20
Slide 14: Lumos Pharma: Summary of Investment Thesis
Lumos Pharma: Summary of Investment Thesis Lumos Pharma • Lead program, LUM-201, with potential to be the (NASDAQ:LUMO) first oral growth hormone secretagogue therapy Transforming Lives for PGHD with Rare Focus • Opportunity to disrupt established and sizable market • Management team with extensive